Skip to main content
HR 8588 116th Congress House Health Congressional oversight Drug safety, medical device, and laboratory regulation Economic performance and conditions Emergency medical services and trauma care Emergency planning and evacuation Government studies and investigations Health care costs and insurance Health technology, devices, supplies Intellectual property Labor market Manufacturing Prescription drugs

Improving the American Drug Supply Chain Act of 2020

Introduced: October 13, 2020 Introduced by: Hudson, Richard Republican · North Carolina See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 13, 2020
Introduced in House
Oct 13, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Improving the American Drug Supply Chain Act of 2020

This bill requires the Department of Health and Human Services to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine to (1) study the current and historical production of drugs and key ingredients in the United States and in foreign countries, and (2) formulate recommendations for promoting increased production of drugs and key ingredients in the United States.

What's happening now October 13, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Related & companion bills 1
  • HR 14 Related bill Commitment to Defeat the Virus and Keep America Healthy Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Democratic 1
D
Blunt Rochester, Lisa
Delaware · Oct 13, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 8588: Improving the American Drug Supply Chain Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-8588/
MLA
"H.R. 8588: Improving the American Drug Supply Chain Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-8588/.
Bluebook (legal)
H.R. 8588, 116th Cong. (2026), https://openamerica.io/bill/116-HR-8588/.
Markdown link
[H.R. 8588: Improving the American Drug Supply Chain Act of 2020](https://openamerica.io/bill/116-HR-8588/)
Report a problem